 Novartis-sponsored, open-label, multi-center, interventional ETP to provide LDK378 to patients with ALK NSCLC, who have been pre-treated with an ALK inhibitor; except in countries where ALK inhibitors are not approved or available. The protocol will further evaluate the safety of LDK378 in patients with ALK NSCLC. 